PEGINTERFERON

作品数：49被引量：175H指数：7
导出分析报告
相关领域：医药卫生更多>>
相关期刊：《World Journal of Hepatology》《中国新药杂志》《World Journal of Gastroenterology》《World Journal of Gastrointestinal Pharmacology and Therapeutics》更多>>
相关基金：国家自然科学基金泰国研究基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B被引量：2
《Biomedical and Environmental Sciences》2022年第4期312-321,共10页LI Ming Hui SUN Fang Fang CHEN Feng Xin ZENG Zhan LIN Yan Jie BI Xiao Yue YANG Liu DENG Wen JIANG Ting Ting HUANG Rong Hai YI Wei XIE Yao 
funded in part by Beijing Hospitals Authority Clinical Medicine Development of Special Funding support[XMLX 201706 and XMLX 202127];the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority[XXZ0302 and XXT28];the National Science and Technology Major Project of China[2017ZX10201201-001-006,2017ZX10201201-002-006,and 2018ZX10715-005-003-005];the Beijing Municipal Science&Technology Commission[Z151100004015122];the Beijing Science and Technology Commission[D161100002716002];the Special Public Health Project for Health Development in Capital[2021-1G-4061]
Objective This study aimed to investigate whether cytokine profiles and virological markers might add value in monitoring the effects of peginterferon(PEG-IFN)therapy for hepatitis B e-antigen(HBeAg)positive chronic h...
关键词：Chronic hepatitis B CYTOKINE PEGINTERFERON HBSAG HBEAG 
Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy被引量：4
《World Journal of Clinical Cases》2020年第11期2255-2265,共11页Wen-Kang Fu Jie Cao Ning-Ning Mi Chong-Fei Huang Long Gao Jin-Duo Zhang Ping Yue Bing Bai Yan-Yan Lin Wen-Bo Meng 
Supported by National Natural Science Foundation of China,No.81872036;Talent Innovation and Entrepreneurship Plan of Chengguan District of Lanzhou City,No.2019RCCX0038;Science and Technology Plan of Chengguan District of Lanzhou City,No.2019JSXC0092.
BACKGROUND Chronic hepatitis B virus infection remains a major global public health problem.Peginterferon-alpha-2a(PEG-IFN)has direct antiviral and immunoregulatory effects,and it has become one of the first choice dr...
关键词：Chronic hepatitis B Peginterferon-alpha-2a Cytokine/chemokine CXCL9 Interferon-inducible protein 10 Thymus and activation-regulated chemokine 
Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients： A Randomized, Multicenter, Phase IIIb Open-Label Study （POTENT Study）被引量：5
《Chinese Medical Journal》2018年第14期1645-1651,共7页Dae Won Jun Sang Bong Ahn Tae Yeob Kim Joo Hyun Sohn Sang Gyune Kim Se Whan Lee Byung Ho Kim Dong Joon Kim Ja Kyung Kim Hyoung Su Kim Seong Gyu Hwang Won Choong Choi Won Young Tak Heon Ju Lee Ki Tae Yoon Byung Cheol Yun Sung Wook Lee Soon Koo Baik Seung Ha Park Ji Won Park Sol Ji Park Ji Sung Lee 
Background： Until now, various types of combined therapy with nucleotide analogs and pegylated interferon （Peg-INF） in patients with hepatitis B patients have been tried. Howe6ver, studies regarding the benefits of...
关键词：ENTECAVIR Hepatitis B Peginterferon Alfa-2a 
Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment:A Long-term Cohort Study被引量：6
《Journal of Clinical and Translational Hepatology》2018年第1期18-24,共7页Yunhua Liu Weikun Li Ting Jia Dan Peng Huimin Li Xiaofei Li Songqin Lv 
The study was supported by the Third People's Hospital of Kunming City, Kunming, China
Background and Aims:The use of additional nucleos(t)ide analogues(NAs)without cross-resistance to previously used NAs as a rescue therapy is recommended by most international guidelines for chronic hepatitis B patient...
关键词：Chronic hepatitis B Peginterferon alfa-2a NA drug resistance HBeAg seroconversion Cohort study 
Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals被引量：11
《Hepatobiliary & Pancreatic Diseases International》2017年第5期470-479,共10页Yan Huang Ming-Hui Li Min Hou Yao Xie 
BACKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained viro...
关键词：chronic hepatitis C direct-acting antivirals hepatitis C virus peginterferon alfa-2a RIBAVIRIN 
Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a被引量：22
《World Journal of Hepatology》2016年第15期637-643,共7页Ming-Hui Li Yao Xie Lu Zhang Yao Lu Ge Shen Shu-Ling Wu Min Chang Cai-Qin Mu Lei-Ping Hu Wen-Hao Hua Shu-Jing Song Shu-Feng Zhang Jun Cheng Dao-Zhen Xu 
AIM: To examine the association between interferon(IFN) therapy and loss of hepatitis B surface antigen(HBs Ag) in inactive HBs Ag carriers. METHODS: This was a retrospective cohort study in inactive HBs Ag carriers, ...
关键词：Chronic hepatitis B surface antigen carriers Inactive hepatitis B surface antigen carriers INTERFERON Peginterferon alfa-2a Hepatitis B surface antigen loss/ seroconversion 
Boceprevir plus peginterferon/ribavirin for treatment ofchronic hepatitis C in Russia
《World Journal of Hepatology》2016年第6期331-339,共9页Vasily Isakov Igor Nikitin Vladimir Chulanov Pavel Ogurtsov Ekaterina Lukyanova Jianmin Long JaniceWahl Frans A Helmond the P08160 Trial Investigators 
AIM: to evaluate addition of boceprevir to peginterferon/ribavirin(PR) in Russian patients with chronic hepatitis C virus(HCV).METHODS: treatment-naive(t N) and treatmentexperienced(t E) patients(who had failed prior ...
关键词：HEPATITIS C virus BOCEPREVIR PEGINTERFERON RIBAVIRIN RANDOMIZED clinical trial SUSTAINED virologicresponse 
Ribavirin:Past,present and future被引量：5
《World Journal of Hepatology》2016年第2期123-130,共8页Véronique Loustaud-Ratti Marilyne Debette-Gratien Jérémie Jacques Sophie Alain Pierre Marquet DenisSautereau Annick Rousseau Paul Carrier 
Before the advent of direct acting antiviral agents(DAAs) ribavirin, associated to pegylated-interferon played a crucial role in the treatment of chronic hepatitis C, preventing relapses and breakthroughs. In the pres...
关键词：RIBAVIRIN HEPATITIS C PEGINTERFERON Directacting ANTIVIRAL agents 
Hepatitis C virus:A global view被引量：8
《World Journal of Hepatology》2015年第26期2676-2680,共5页Amal Ahmed Mohamed Tamer A Elbedewy Magdy El-Serafy Naglaa El-Toukhy Wesam Ahmed Zaniab Ali El Din 
Hepatitis C virus(HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma(HCC), and end-stage l...
关键词：HEPATITIS C PEGINTERFERON Sofosbuvir Direct-acting 
Current and future directions for treating hepatitis B virus infection被引量：16
《World Journal of Hepatology》2015年第11期1541-1552,共12页Akinobu Tawada Tatsuo Kanda Osamu Yokosuka 
Hepatitis B virus(HBV) persistently infects approximately 350 million people, and approximately 600000 liverrelated deaths are observed per year worldwide. HBV infection is also one of the major risk factors for hepat...
关键词：HEPATOCELLULAR carcinoma PEGINTERFERON NUCLEOTIDE ANALOGUE Chronic HEPATITIS B 
全选清除导出
共5页<12345>
检索报告 对象比较 聚类工具 使用帮助 返回顶部